Description
Latin name
ACTOVEGIN
Release form
Injection solution is clear, yellowish, practically free of particles.
Packing
10 ml – clear glass ampoules (5) – contour plastic cell packaging (1) – packs of cardboard.
Pharmacological action
antihypoxant. Actovegin is a hemoderivative, which is obtained by dialysis and ultrafiltration (compounds with a molecular weight of less than 5000 daltons pass).
Positive effect on the transport and utilization of glucose, stimulates oxygen consumption (which leads to stabilization of the plasma membranes of cells during ischemia and a decrease in the formation of lactates), thus possessing an antihypoxic effect that begins to manifest itself at the latest 30 minutes (10-30 minutes) after parenteral administration and reaches a maximum and average after 3 hours (2-6 hours).
Actovegin increases the concentration of ATP, LDF, phosphocreatine, as well as amino acids – glutamate, aspartate and GABA.
The use of Actovegin to accelerate wound healing is also based on the above data. Moreover, not only morphological, but also the biochemical parameters of granulation – increased DNA concentration. hemoglobin and hydroxyproline.
Indications
metabolic and vascular disorders of the brain (including ischemic stroke, traumatic brain injury)
peripheral (arterial and venous) vascular disorders and their consequences (arterial angiopathy, trophic ulcers)
healing of various wounds (ulcers , burns, trophic disorders (bedsores), impaired wound healing processes)
prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy.
Contraindications
hypersensitivity to Actovegin ® or similar drugs
decompensated heart failure
pulmonary edema
oliguria, anuria
fluid retention.
Precautions: hyperchloremia, hypernatremia.
Use during pregnancy and lactation
Use of the drug in pregnant women did not cause a negative effect on the mother or fetus.
However, when used in pregnant women, the potential risk to the fetus must be considered.
Composition of
1 ampoule contains:
active substance:
Actovegin ® concentrate (in terms of dry deproteinized hemoderivative of calf blood) 1) – 400.0 mg
excipient:
water for injection – up to 10 ml.
1) Actovegin ® concentrate contains sodium chloride in the form of sodium and chlorine ions, which are components of calf blood.
Sodium chloride is not added or removed during the production of the concentrate.
The sodium chloride content is about 53.6 mg (for 2 ml ampoules), about 134.0 mg (for 5 ml ampoules) and about 268.0 mg (for 10 ml ampoules).
Dosage and administration of
V / a, iv (including as infusion) and / m. In connection with the potential for the development of anaphylactic reactions, it is recommended to conduct a test before the start of the infusion.
Depending on the severity of the clinical picture, 10-20 ml / day iv or iv and then 5 ml iv or 5 ml iv.
When administered in the form of infusion to 200-300 ml of the main solution (0, 9% sodium chloride solution or 5% dextrose solution) add 10-20 ml of Actovegin ®. Speed of administration: about 2 ml / min.
Metabolic and vascular disorders of the brain: at the beginning of treatment, 10 ml iv daily for two weeks, then 5-10 ml iv 3 4 times a week for at least 2 weeks.
Ischemic stroke: 20-50 ml in 200-300 ml of the main solution in / drip daily for 1 week, then 10 – 20 ml in / drip 2 weeks.
Peripheral (arterial and venous) vascular disorders and their consequences: 20-30 ml of the drug in 200 ml of the main solution in / a or iv daily treatment duration of about 4 weeks.
Wound healing: 10 ml iv or 5 ml iv daily or 3-4 times a week, depending on the healing process (in addition to local treatment with Actovegin ® in topical dosage forms).
Prevention and treatment of radiation injuries of the skin and mucous membranes during radiation therapy: the average dose is 5 ml iv daily during breaks of radiation exposure.
Radiation cystitis: daily 10 ml transurethrally in combination with antibiotic therapy.
Side effects
Allergic reactions (skin rash, hyperemia of the skin, hyperthermia) up to anaphylactic shock.
Drug Interaction
Currently unknown.
Storage conditions
At a temperature not exceeding 25 ° C in a dark place.
Keep out of the reach and sight of children!
Shelf life
3 years. Do not use after expiration date.
Deystvuyushtee substance
Deproteinizirovann y gemoderivat Resurrection facturer
Terms and conditions
prescription
dosage form
injection
Prescription
Prescription
For I am an adult as prescribed by a doctor, Pregnant as prescribed by a doctor
Takeda GmbH, Russia
